The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Volume 337:1785-1791 December 18, 1997 Number 25
NextNext

Preoperative Amiodarone as Prophylaxis against Atrial Fibrillation after Heart Surgery
Emile G. Daoud, M.D., S. Adam Strickberger, M.D., K. Ching Man, D.O., Rajiva Goyal, M.D., G. Michael Deeb, M.D., Steven F. Bolling, M.D., Francis D. Pagani, M.D., Cynthia Bitar, R.N., Marc D. Meissner, M.D., and Fred Morady, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Atrial fibrillation occurs commonly after open-heart surgery and may delay hospital discharge. The purpose of this study was to assess the use of preoperative amiodarone as prophylaxis against atrial fibrillation after cardiac surgery.

Methods In this double-blind, randomized study, 124 patients were given either oral amiodarone (64 patients) or placebo (60 patients) for a minimum of seven days before elective cardiac surgery. Therapy consisted of 600 mg of amiodarone per day for seven days, then 200 mg per day until the day of discharge from the hospital. The mean (±SD) preoperative total dose of amiodarone was 4.8±0.96 g over a period of 13 ± 7 days.

Results Postoperative atrial fibrillation occurred in 16 of the 64 patients in the amiodarone group (25 percent) and 32 of the 60 patients in the placebo group (53 percent) (P = 0.003). Patients in the amiodarone group were hospitalized for significantly fewer days than were patients in the placebo group (6.5 ± 2.6 vs. 7.9 ± 4.3 days, P = 0.04). Nonfatal postoperative complications occurred in eight amiodarone-treated patients (12 percent) and in six patients receiving placebo (10 percent, P = 0.78). Fatal postoperative complications occurred in three patients who received amiodarone (5 percent) and in two who received placebo (3 percent, P = 1.00). Total hospitalization costs were significantly less for the amiodarone group than for the placebo group ($18,375±$13,863 vs. $26,491±$23,837, P = 0.03).

Conclusions Preoperative oral amiodarone in patients undergoing complex cardiac surgery is well tolerated and significantly reduces the incidence of postoperative atrial fibrillation and the duration and cost of hospitalization.


Source Information

From the Division of Cardiology, Department of Internal Medicine (E.G.D., S.A.S., K.C.M., R.G., C.B., F.M.), and the Division of Thoracic Surgery, Department of Surgery (G.M.D., S.F.B., F.D.P.), University of Michigan Hospital, Ann Arbor; and the Division of Cardiology, Department of Internal Medicine, Harper Hospital, Wayne State University, Detroit (M.D.M.).

Address reprint requests to Dr. Daoud at the Midwest Cardiology Research Foundation, Riverside Methodist Hospital, 3545 Olentangy Rd., Rm. 325, Columbus, OH 43214.

Full Text of this Article


Related Letters:

Amiodarone Prophylaxis for Atrial Fibrillation after Cardiac Surgery
McCullough P. A., Redle J. D., Zaman A. G., Archbold A., Alamgir F., Ulahannan T. J., Daoud E. G., Morady F.
Extract | Full Text  
N Engl J Med 1998; 338:1383-1384, May 7, 1998. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.